Article Text

Download PDFPDF
Infliximab failure in cap polyposis
  1. V Maunoury,
  2. M Breisse,
  3. P Desreumaux,
  4. L Gambiez,
  5. J-F Colombel
  1. Clinique des Maladies de l’Appareil Digestif et al de la Nutrition, Centre Hospitalier Universitaire Lille, Lille, France
  1. Correspondence to:
    Professor J-F Colombel
    Clinique des Maladies de l’Appareil Digestif et al de la Nutrition, Centre Hospitalier Universitaire Lille, CH et al U Lille, 59037, Lille, France; jfcolombelchru-lille.fr

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Cap polyposis is a rare condition that predominantly affects the rectosigmoid with distinctive clinicopathological features. The common symptoms are mucoid and bloody diarrhoea with abdominal pain and tenesmus. At endoscopy, polyps are red, sessile, and located at the apices of enlarged transverse mucosal folds with a normal intervening mucosa. Microscopic features include elongated hyperplastic looking glands with a mixed inflammatory infiltrate in the lamina propria. A cap of fibrinopurulent exudate covers the polyps. Treatment of this condition remains empiric. Metronidazole and steroids have been effective in some cases. Symptoms are often relieved by polypectomy but rectosigmoid resection may be required …

View Full Text

Footnotes

  • Conflict of interest: None declared.